Actively Recruiting
Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain
Led by Stanford University · Updated on 2026-04-24
95
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to examine non-invasive pulsed radiofrequency (NIPRF) and the effect it has on chronic neuropathic pain. Chronic neuropathic pain after peripheral nerve injury most often occurs in the context of post-traumatic or post-surgical pain. It is often treated with nerve blocks, prescription medication, physical therapy, neuromodulation, and surgery. The study team will be examining the efficacy of NIPRF and determining if it would be an appropriate treatment for chronic neuropathic pain after peripheral nerve injury.The Stimpod used in the present study is FDA approved and will be used for on label purposes.
CONDITIONS
Official Title
Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 or older with clinically diagnosed chronic neuropathic pain after peripheral nerve injury
- Neuropathic pain caused by peripheral nerve lesion with history of nerve trauma and pain distribution matching affected nerve
- Positive response with at least 50% pain relief to diagnostic nerve block at the suspected pain site
- Continued pain despite conservative therapy for at least 12 weeks
- Stable analgesic medication dose for at least 30 days and willingness to avoid new analgesics for 3 weeks after randomization
- Worst pain intensity of 5 or greater on a 0-10 Numeric Rating Scale at enrollment
- English-speaking
- Ability and willingness to complete online and phone assessments
You will not qualify if you...
- Inability to complete assessments due to education, cognitive, mental, or medical status
- Active cancer diagnosis, malignant neoplasm, or paraneoplastic syndrome
- Painful polyneuropathy from metabolic, autoimmune, familial, infectious, toxin, or neurotoxic drug causes
- Chronic central neuropathic pain from spinal cord injury, brain injury, multiple sclerosis
- Peripheral vascular disease
- Diabetic neuropathy
- Presence of other active implantable devices (e.g., defibrillator, spinal cord stimulator, intrathecal pump)
- Pregnancy, breastfeeding, or planning to conceive
- Systemic or local infection at treatment sites
- Interventional procedure or surgery for neuropathic pain within last 30 days (or 3 months for ablative treatment)
- Epilepsy
- Metal implants within the target treatment area of NIPRF
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford Pain Management Center
Redwood City, California, United States, 94063
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here